-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, China Pharmaceutical (600056.SH) issued an announcement. Recently, Tianfang Pharmaceutical Co., Ltd. (“Tianfang Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of mupirocin's “Notice of Approval of the Marketing Application for Chemical Ingredients” issued by the State Drug Administration. This drug is mainly used for skin and soft tissue infections caused by gram-positive cocci, such as primary infections such as impetigo, acne, and folliculitis, and secondary infections of skin diseases such as eczema, dermatitis, ulcers, and trauma.
Share
Listen to the news
Zhitong Finance App News, China Pharmaceutical (600056.SH) issued an announcement. Recently, Tianfang Pharmaceutical Co., Ltd. (“Tianfang Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of mupirocin's “Notice of Approval of the Marketing Application for Chemical Ingredients” issued by the State Drug Administration. This drug is mainly used for skin and soft tissue infections caused by gram-positive cocci, such as primary infections such as impetigo, acne, and folliculitis, and secondary infections of skin diseases such as eczema, dermatitis, ulcers, and trauma.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending